Dioscorea zingiberensis Extract (Diosgenin 98%): Raw Material, Grades, and Environmental Constraints
| CAS No. | 512-04-9 |
|---|---|
| Molecular formula | C27H42O3 |
| Relative molecular mass | 414.62 |
| Appearance | Off-white crystalline powder |
| Melting point | 204–207 °C (literature value) |
| Specific rotation | About −126° (c 1, chloroform) |
| Assay | Diosgenin ≥98% (HPLC; must state external standard or area normalization) |
| Common grades | 98% |
| Test method | HPLC-UV 203 nm; acetonitrile required (methanol cut-off 205 nm) |
Definition in One Sentence
Dioscorea zingiberensis extract is a diosgenin product (CAS 512-04-9) made from the dried rhizomes of the Dioscoreaceae plant Dioscorea zingiberensis C.H. Wright by acid hydrolysis of the sugar chains, solvent extraction, and crystallization. Our specification is ≥98%, with a measured batch of 98.07%. It is a starting material for steroidal hormone drugs, not a dietary-supplement ingredient. It is the same compound as diosgenin from Dioscorea nipponica; the difference lies in purity grade and raw-material route.
Product Identity: Four Quoting Units Along One Chain, All Called "Saponin"
There are four quoting units for Dioscorea zingiberensis extract along the value chain; from fresh rhizome to 16-DPA the material passes through four hands, and at every stage someone calls the product "saponin". Comparing prices across them carelessly easily produces a discrepancy of an order of magnitude:
| Stage | Trade name | Assay basis | Form | Who buys |
|---|---|---|---|---|
| Raw material | Fresh huangjiang rhizome / dried slices | Diosgenin 2.0%–3.0% (registered cultivars) | Mud-covered or sliced | Diosgenin plants, collectors |
| Intermediate | Diosgenin hydrolysate | Typically 85%–95%, calculated on the hydrolysate | Yellow-brown to off-white powder | 16-DPA plants |
| Single component | Diosgenin ≥98% | Above 98%, HPLC | Off-white crystalline powder | Steroid synthesis, reference standards, trading |
| Downstream | 16-DPA | ≥98% | Crystals | Steroid API manufacturers |
All four are abbreviated to "saponin", with prices from a few yuan to over a thousand yuan per kilogram. The first question in an inquiry should be "which stage of the chain, on what assay basis, tested by what method" — not "how much is saponin per tonne".
The trade name "huangjiang extract" is itself ambiguous: some on the market mean diosgenin from huangjiang (our usage), others mean a water extract or a flavonoid extract of the rhizome. The compositions are completely different. Put the product name, CAS number, and assay into the contract before ordering; do not write only "huangjiang extract".
Botanical Source: The Only Mainstream Feedstock in the Dioscoreaceae That Is Not a Pharmacopoeial Drug
The 2025 Edition, Volume I of the Chinese Pharmacopoeia lists five Dioscoreaceae crude drugs, and Dioscorea zingiberensis — the feedstock for huangjiang extract — is not among them, so this category has no statutory crude-drug standard to rely on.
| Pharmacopoeial drug | Scientific name | Statutory marker | Relation to diosgenin |
|---|---|---|---|
| Chinese yam | Dioscorea opposita Thunb. | No diosgenin assay item (moisture, ash, extractives) | Low diosgenin content; making a 40% extract requires enrichment |
| Dioscorea nipponica | D. nipponica Makino | Dioscin ≥1.3% (HPLC-UV, 203 nm) | The feedstock for our 92% diosgenin, with a statutory minimum to rely on |
| Dioscorea hypoglauca | D. hypoglauca Palibin | Qualitative identification of diosgenin | Mainly medicinal; not used as industrial diosgenin feedstock |
| Dioscorea spongiosa | D. spongiosa / D. futschauensis | Extractives, ash | Mainly medicinal |
| Dioscorea panthaica | D. panthaica Prain et Burkill | Steroidal saponins (raw material for Di'ao Xinxuekang) | Industrially extracted, but on a smaller scale than huangjiang |
Dioscorea zingiberensis is not on this list. It is an easily overlooked fact with wide implications:
- There is no statutory crude-drug standard to rely on. Dioscorea nipponica has a pharmacopoeial minimum of 1.3% dioscin, giving acceptance a recognised anchor; huangjiang raw material has none, so how content is measured and what basis it is calculated on can only come from the contract or a group standard.
- It cannot enter a downstream pharmaceutical company's supplier system through the "crude drug" route. It follows the chemical raw material / pharmaceutical intermediate route, so qualification, audit, and batch-record requirements follow the chemical and GMP-intermediate regime.
- Its origin claims are not bound by the crude-drug "authentic region" system. For pharmacopoeial species there is industry consensus on producing areas and processing; for huangjiang, origin can only be judged from planting records and a company's own bases.
For this reason the Shaanxi Province Standardization Association issued group standard T/SXBX 22-2026, Technical Specification for the Production of Huangjiang Diosgenin, in April 2026, linking raw-material requirements, production technology, quality control, inspection rules, and packaging and storage into one chain, with the scope explicitly stating "using Dioscorea zingiberensis as the main raw material". The drafting organisations are five southern Shaanxi companies including Shaanxi Yonghong Biotechnology, Fangyu Pharmaceutical, and Suqin Jiahong. It is currently the only written full-chain technical basis for this category.
The Raw-Material Industry: Area Shrinking, Capacity Idle
The raw-material end of huangjiang extract presents a counter-intuitive situation: huangjiang is not a scarce plant; what is scarce is people willing to grow it, and that is the real source of price volatility.
The Qinba Mountains of southern Shaanxi (Baihe, Xunyang, and Pingli in Ankang; the Zhenba area in Hanzhong) are China's core huangjiang producing area. Baihe County has the most complete chain: annual output of 500 tonnes of diosgenin (hydrolysate) and 400 tonnes of 16-DPA, with an output value of 655 million yuan in 2025; the county's core enterprise can process 75,000 tonnes of huangjiang a year, holds about 75% of the diosgenin (hydrolysate) market, and is the largest single plant in the country by capacity.
But the same publicly available government material is blunt:
| Indicator | Current situation | Cause |
|---|---|---|
| County huangjiang area retained | Under 20,000 mu (including that year's new planting) | Many mountain households moved out under relocation programmes; the income gap between growing huangjiang and working elsewhere is wide |
| Processing capacity utilisation | More than 50% idle | Insufficient raw material; the three above-scale enterprises are often semi-shut down |
| Yield per mu (fresh) | Over 1,400 kg (high-yield parks) | Improved cultivation; previously under 1,000 kg |
| Harvest age | 3 years | Diosgenin accumulates with age; two-year material has insufficient content |
What this means for buyers: the price risk here is not "the plant raises prices" but "the plant cannot get huangjiang". When raw material is tight, plants serve long-term customers first and lead times for spot orders stretch; conversely, stock left over from the expansion years of planting creates windows of low prices. To judge whether a quote is sustainable, look not at the plant's size but at whether it has its own bases — "company + base + growers" is not a slogan in this category, it is capacity assurance.
Material Balance: 150 Tonnes of Fresh Huangjiang per Tonne of Diosgenin
When a negotiation over huangjiang extract reaches a deadlock, returning to the material balance resolves most of the questions, because the ratio of 150 tonnes of fresh huangjiang to 1 tonne of diosgenin is the price floor.
Calculated from the 2.0%–3.0% diosgenin content of registered cultivars (on a dry basis):
| Step | Assumption | Intermediate quantity |
|---|---|---|
| Fresh huangjiang | About 60% moisture, 40% dry-matter recovery | 100 t fresh → 40 t dry |
| Diosgenin on dry basis | Midpoint 2.5% | 40 t × 2.5% = 1.0 t |
| Hydrolysis and extraction yield | 65%–70% (cumulative losses in acid hydrolysis, solvent extraction, and crystallization) | 1.0 × 0.68 ≈ 0.68 t |
| Normalised to 100% diosgenin | — | About 150 t fresh rhizome per tonne |
This calculation can be cross-checked against public data: Baihe's core enterprise processes 75,000 tonnes of huangjiang a year and produces 500 tonnes of diosgenin (hydrolysate) — a ratio of exactly 150:1. Two independent routes agree, so the order of magnitude is reliable.
Converting to land:
- at 1,400 kg of fresh rhizome per mu, one tonne of diosgenin needs 150 t ÷ 1.4 t/mu ≈ 107 mu;
- on the theoretical 100 t figure, about 71 mu;
- with a three-year growth cycle, those 71–107 mu are tied up for three years for each tonne of diosgenin.
These three numbers (150 tonnes, 100 mu, 3 years) explain the rigidity of pricing better than any adjective. They are also the first filter for the provenance of "cheap material" — a quote below this material-cost floor means either stock being cleared or a problem with the assay basis.
The 98% Grade: How It Differs from 92%
Diosgenin is the same molecule, yet 98% and 92% are two different purity grades, and the uses and pricing logic of huangjiang extract and Dioscorea nipponica extract are therefore entirely different.
| Item | 98% from huangjiang | 92% from Dioscorea nipponica |
|---|---|---|
| CAS | 512-04-9 | 512-04-9 (the same compound) |
| Assay (HPLC) | ≥98%, batch measured 98.07% | ≥92%, batch measured 93.11% |
| Appearance | Off-white crystalline powder | White to off-white powder |
| Main use | Steroid synthesis feedstock, reference standards and qualitative studies, high-purity trading | Routine steroid synthesis feedstock |
| Pricing logic | More expensive raw material plus one extra purification step | Pharmacopoeial crude-drug status, with a statutory minimum for the raw material |
| Acceptance difficulty | Melting point deviates from the literature value (see next section) | Melting point and specific rotation both fall mid-range |
98% is not "a better 92%"; they are two different businesses. 92% serves bulk synthesis feedstock, where the buyer looks at cost per kilogram of diosgenin and batch consistency; 98% serves impurity-sensitive applications — reference-standard preparation, pilot scale-up, high-purity export orders — where the buyer looks at chromatograms, isomer ratio, and batch consistency. Pressing a 98% quote down to a 92% price, or holding a 92% batch to 98% standards, is a mismatch either way.
One frequently overlooked specification variable: on what basis the 98% is reported. HPLC area normalization, external standard, or titration/colorimetry can differ by 1–2 percentage points. At the 98% grade, 2 points is the line between compliant and non-compliant. The contract must state the method, column, wavelength, and source of the reference standard.
A Real Batch: The 201 °C Melting Point Is a Signal
Batch 26040201 of huangjiang extract was tested on 2026-04-06 against the company standard.
| Test item | Specification | Measured |
|---|---|---|
| Assay | Diosgenin ≥98% | 98.07% |
| Appearance | Off-white powder | Off-white powder, conforms |
| Melting point | 190 °C (in-house floor) | 201 °C |
| Specific rotation | −120° to −126° | −122.5° |
| Moisture | No limit stated in the report | 0.33% |
| Heavy metals | Not in the report | — |
| Microbial limits | Not in the report | — |
There is one point in this batch worth questioning: 98% purity, but a melting point of only 201 °C.
The literature melting point for diosgenin is 204–207 °C. Our 92% batch from Dioscorea nipponica measured 207 °C — the lower-purity batch melts 6 degrees higher. That is counter-intuitive in direction, since impurities usually lower the melting point.
The specific rotation of −122.5° is identical to the 92% batch, which narrows the possibilities: if the 25S epimer (yamogenin, CAS 512-06-1) were contaminating the batch, the melting point would drop and the specific rotation would shift markedly; the two batches agree, so the isomer is not the main cause.
The remaining explanations, in order of likelihood:
- Residual solvents. Ethanol or petroleum ether left from the crystallization mother liquor markedly depresses the initial melting point, and HPLC area normalization cannot see solvents (they do not peak, or elute in the dead volume). This is the most common cause.
- Differences in the test method. An in-house limit stating only a 190 °C floor suggests a capillary method with a fast heating rate; fast heating reads low.
- Polymorph differences. Different crystallization solvents and cooling rates give different crystal forms, with melting points several degrees apart.
- Instrument calibration. A melting-point apparatus not calibrated against a standard carries a systematic bias.
What the buyer should do: a melting point outside the literature range is not grounds for rejection (the 190 °C in-house standard is met), but it is grounds for questions. Ask for a residual-solvent test (GC), the raw melting-point curve, and a clear answer on the heating rate. If the supplier cannot answer, this batch's 98% rests on a single HPLC number and the buyer carries the risk.
6.1 What This COA Is Missing
- Heavy metals and harmful elements: the whole section is missing. Diosgenin goes through acid hydrolysis, so lead, arsenic, and cadmium carried in by equipment and solvents are a real risk, and the EU checks them on import;
- Microbial limits: the whole section is missing;
- Residual solvents: ethanol and petroleum ether are routine solvents in this process; not declaring them leaves a blank;
- Loss on drying / residue on ignition: indirect indicators of residual inorganic salts and moisture;
- Related substances and chromatograms: 98% purity should be traceable to a trace and impurity peak areas, not just a percentage;
- 25R/25S isomer ratio: the most easily overlooked specification variable in the diosgenin trade; high-purity orders should list it separately.
Process and Environment: The Historical Burden of This Product Line
The mainstream process for huangjiang diosgenin is the acid hydrolysis route: grind the rhizome → acid hydrolysis to cleave the sugar chains → solvent extraction (gasoline or petroleum ether) → crystallization and purification → drying. It is mature, high-yielding, and has a low equipment barrier — but it has a cost.
Environmental performance is a structural constraint on this chain, not a management failure at individual plants.
| Stage | Main burden | Current situation |
|---|---|---|
| Acid hydrolysis | High-strength acidic wastewater with high COD, deep colour, and poor biodegradability | The mainstream treatment for the traditional process is neutralisation plus biological treatment, which is expensive |
| Solvent extraction | Volatilisation losses and recovery of gasoline / petroleum ether | Recovery rate directly determines cost and safety class |
| Hydrolysis residue | Large volumes of starch and cellulose residue | Increasingly converted into carbon sources and carbon-based fertiliser, forming a circular chain |
| Downstream Marker degradation | Chromic acid oxidation to 16-DPA, producing chromium-bearing waste liquor | A historical environmental burden of the steroid industry |
According to industry research, cleaner processes (enzymatic hydrolysis, microbial fermentation pretreatment, and similar) accounted for about 19% of capacity in 2025; most capacity remains on the traditional acid hydrolysis route. Technical breakthroughs in cleaner processes have been reported, but scale-up from laboratory to industrial operation, equipment adaptation, and cost control are still being worked out.
What this means for buyers: a supplier's environmental compliance translates directly into supply continuity. A plant under production restrictions or suspended for remediation cannot deliver, however cheap its quote. During a factory audit, put wastewater treatment, online monitoring, and hazardous-waste transfer manifests on the must-see list — more useful than looking at floor area.
Upstream, Baihe County has built a circular chain of "huangjiang diosgenin — 16-DPA — carbon source — carbon-based fertiliser" that uses the hydrolysis residue completely — a comparatively complete solution for this category, and an explanation of why core capacity is concentrated in a handful of counties.
Standards and Regulations: The Group Standard Is Currently the Only Full-Chain Basis
| Basis | Nature | Scope | Binding force |
|---|---|---|---|
| Chinese Pharmacopoeia, 2025 Edition | Statutory drug standard | Does not include Dioscorea zingiberensis | Not applicable |
| T/SXBX 22-2026, Technical Specification for the Production of Huangjiang Diosgenin | Group standard (Shaanxi Province Standardization Association) | Raw-material requirements, production technology, quality control, inspection rules, packaging and storage | Voluntary adoption; may be cited by agreement in a contract |
| Company standard | Set by the company | Differs between plants; our batch follows it | Binding by contract |
| Target-market regulations (EU / US) | Importing-country requirements | Residual solvents, heavy metals, supplier audits | Mandatory |
There are only two compliance routes for huangjiang extract: a group standard plus a contract, or target-market regulations plus supplier audits. The pharmacopoeia is of no help on this product line.
- The group standard is currently the text closest to an industry consensus. It was issued and implemented on 2026-04-16, drafted by the main producers in the producing area, and covers everything from raw material to storage and transport. Making it a technical annex to the contract is more binding than writing only "conforms to the company standard". Note that its English title is printed as "turmeric saponin" (turmeric being Curcuma), a translation error; cite the Chinese title instead.
- The bar for exporting to the EU is rising. EU limits on residual solvents and heavy metals in saponin hydrolysate are tightening, and supplier-audit requirements are becoming more detailed. For export batches, those two sections of the COA cannot be left blank.
- No efficacy claims can be made for it. It is an industrial intermediate for steroid synthesis — not a food ingredient, not a health-food ingredient, not a crude drug. Any functional claim made under the name "huangjiang extract" lacks a regulatory basis.
Procurement and QC Checklist
9.1 Six Things to Clarify When Requesting a Quote
- The assay basis: HPLC external standard or area normalization, plus the wavelength and source of the reference standard;
- Measured melting point and specific rotation, with the test method and heating rate;
- A residual-solvent report (GC), especially for ethanol and petroleum ether;
- Heavy metals, all four (lead, arsenic, cadmium, mercury), and microbial limits;
- The 25R/25S isomer ratio, or at least a statement that the figure is calculated as the 25R form;
- Raw-material source: own base, contract base, or open-market purchase, and whether charge records can be provided.
9.2 Five Common Risk Points
- Swapped assay basis: quoting the hydrolysate's "85%–95% on the hydrolysate" as if it were the 98% single component;
- Isomers not declared: a high 25S proportion with a clean single HPLC peak, but insufficient actual purity;
- Vague melting-point data: only "conforms", with no measured value or method;
- Missing chromatograms: 98% as a bare number, with no trace matched to the batch number;
- Unknown raw-material provenance: no traceable charge records, and no way to rule out admixture of other Dioscorea species.
9.3 Focus of a Factory Audit
The audit checklist for huangjiang extract can be compressed into six items, the first two bearing directly on supply continuity and the last four determining batch consistency: wastewater treatment and online monitoring; hazardous-waste transfer manifests; solvent recovery equipment; the cleanliness class of the crystallization workshop; batch-record traceability (can a record be traced to the specific equipment, shift, and operator); and batch labelling in the raw-material and finished-goods warehouses.
Frequently Asked Questions
Q1: Are huangjiang, turmeric, and ginger the same thing?
No. Huangjiang is the rhizome of Dioscorea zingiberensis (Dioscoreaceae), used to extract diosgenin; turmeric is the rhizome of Curcuma longa (Zingiberaceae), whose main constituent is curcumin; ginger is the fresh rhizome of Zingiber officinale, a food. They differ entirely in family, composition, and use, and cannot substitute for one another. Search results for "huangjiang" that pull in turmeric are the most common starting error in this kind of procurement.
Q2: Can 98% huangjiang diosgenin be used as a reference standard?
It can serve as a working standard or for qualitative studies, but it cannot replace an official reference standard. Official standards have assigned values and uncertainty; a commercial 98% diosgenin does not. If used for assay, it must be calibrated and the calibration documented.
Q3: Why does the 98% grade melt lower than the 92%?
See Section 6. The most likely causes are residual solvent or differences in the test method, not purity; but the supplier must be asked for an explanation and supporting data, otherwise this batch's purity rests on a single HPLC number.
Q4: Are diosgenin from huangjiang and from Dioscorea nipponica interchangeable?
Chemically yes — both are CAS 512-04-9. Commercially not entirely: Dioscorea nipponica has pharmacopoeial crude-drug status and a statutory marker, huangjiang does not; when export or customer audits require raw-material traceability, the documentation burden differs. The contract should state the botanical source to prevent substitution at delivery on the grounds that it is "the same compound".
Q5: Why is huangjiang diosgenin so volatile in price?
The root is at the farming end: a three-year growth cycle, limited yield per mu, and low comparative returns mean that once growers abandon the crop, supply recovers slowly; processing capacity, by contrast, is rigid, so when raw material tightens, plants bidding for it push prices up. Conversely, stock built up during earlier expansion years creates windows of low prices. To judge whether a quote is sustainable, look at whether the plant has its own bases.
Q6: Can I accept a COA without heavy metals and microbial limits?
For general domestic industrial use it can be negotiated, but for export, pharmaceutical intermediates, or customers with in-house requirements, it is a hard gap. Ask for the missing tests to be added, or switch to a batch with a complete set — the heavy-metal risk of an acid hydrolysis process should not be ruled out by "not tested".
Q7: Can this product be used in food or health products?
Not advisable, and there is no regulatory basis. Diosgenin is an industrial intermediate for steroid synthesis and is not a food ingredient or food-medicine substance; huangjiang itself is not on the food-medicine substances catalogue either. Formulation work should use other ingredients with a clear food status.
Q8: For a three-point gap between 98% and 95%, what price difference is reasonable?
There is no fixed ratio; it depends on the number of purification passes and raw-material cost. The way to judge is to convert to "per kilogram of diosgenin": divide the unit price by the assay to get a comparable diosgenin price, then see whether the difference matches the cost of an extra purification pass. Comparing finished-product prices per kilogram directly mistakes an assay difference for a price difference.
References and Search Suggestions
- Chinese Pharmacopoeia, 2025 Edition, Volume I, monographs for Chinese yam, Dioscorea nipponica, Dioscorea hypoglauca, Dioscorea spongiosa, and Dioscorea panthaica — used to verify the pharmacopoeial scope and statutory markers; Dioscorea zingiberensis is not among them, a conclusion drawn from checking this table of contents.
- T/SXBX 22-2026, Technical Specification for the Production of Huangjiang Diosgenin, Shaanxi Province Standardization Association, issued and implemented 2026-04-16 — searchable by standard number on the National Group Standard Information Platform; the scope runs from raw-material requirements to packaging and storage.
- Ankang Municipal Finance Bureau, "Proposal on Promoting the Healthy and Sustainable Development of the Huangjiang Pharmaceutical Industry" (response to Proposal No. 19) — the public source for the retained huangjiang area in Baihe County, the idle-capacity ratio, diosgenin and 16-DPA capacity, annual processing volume, and market share.
- Baihe County Market Supervision Administration, "Baihe: Coordinating Efforts to Promote High-Quality Development of the Huangjiang Pharmaceutical Industry" — the structure of the circular chain, purchase volumes, and output value.
- Ankang Daily, "Golden Fruit on the Loess Slope" — a producing-area example of yield per mu and harvest age.
- Shaanxi Provincial Forestry Department, 2009 huangjiang cultivar registration announcement, and materials on the cultivar "Anjiang 2" — the source for the 2.0%–3.0% rhizome diosgenin content of registered cultivars. Item 6 gives a search path rather than a specific citation; follow it to retrieve and verify the original when needed.
- PubChem CID 99474 / NIST WebBook — basic data for diosgenin: CAS 512-04-9, molecular formula C₂₇H₄₂O₃, molecular weight 414.62.
- The original methodological literature on Marker degradation (acetylation of diosgenin followed by chromic acid oxidation to 16-DPA) — locate it by searching "Marker degradation diosgenin 16-DPA"; this item gives a search path rather than a specific citation.
- Industry research on the share of cleaner-process capacity in 2025 (about 19%) — an industry research estimate rather than an official statistic; its nature should be noted when cited.
Disclaimer
This article is technical reference material on raw materials, intended for R&D, procurement, and quality personnel; it does not constitute medical advice, dosing guidance, or compliance advice. Assay, process, and regulatory information change as standards are revised; for actual transactions and filings, rely on the latest official standards, the terms agreed in the contract, and third-party test reports.